Coherent Market Insights

Vaccine Adjuvant Market to Surpass 3,521.5 Mn by 2028

Vaccine Adjuvant Market to Surpass 3,521.5 Mn by 2028 - Coherent Market Insights

Publish On: Jan 04, 2023

Vaccine adjuvants are used to create a stronger immune response in people receiving the vaccine or to enhance the immune response of vaccine. Adjuvants are critical components of both subunit and certain inactivated vaccines. An adjuvant is a component that boosts the immune response to the vaccine. Adjuvants are defined as components capable of enhancing and/or shaping antigen-specific immune responses. New adjuvants have been developed to target specific components of the body’s immune response, so that protection against disease is stronger and lasts longer.

Market Statistics:

The global Vaccine Adjuvant Market is estimated to account for US$ 1,625.6 Mn in terms of value by the end of 2022.

Drivers:

Increase in focus on the development of safe and effective vaccines (to treat various infectious and chronic diseases) across the world is expected to boost the growth of the global Vaccine Adjuvant Market. For instance, with the increase in prevalence of infectious and chronic diseases, the use of vaccine adjuvants for vaccine development is also increasing with rapid pace. In April 2022, GSK and SK bioscience submitted a biologics license application to the Korean Ministry of Food and Drug Safety (KMFDS) for their SKYCovione following positive clinical data. It is a recombinant protein-based COVID-19 vaccine candidate adjuvanted with GSK’s adjuvant.

Opportunities:

Favorable government initiatives or government initiatives for immunization are expected to offer significant growth opportunities for players in the global Vaccine Adjuvant Market. For instance, immunization prevents severe illness, and safeguard from the vaccine-preventable disease. Indian Government’s Universal Immunization Programme (UIP) provide free vaccines against twelve life threatening diseases, to over 26 million children every year. UIP provides life-saving vaccines to all children to protect them against Tuberculosis, Polio, Pertussis, Diphtheria, Tetanus, Pneumonia, Hepatitis B, and Meningitis owing to Haemophilus Influenzae type b, Measles, Rubella, Japanese Encephalitis (JE), and Rotavirus diarrhoea.

Restraints:

High R&D cost of developing new adjuvants, side effects of vaccine adjuvants, and high toxicity of vaccine adjuvants are major factors expected to hamper growth of the global Vaccine Adjuvant Market. For instance, vaccine adjuvants possess various moderate to severe side effects; in some cases, they also cause adverse events. According to the Centers for Disease Control and Prevention (CDC), adjuvanted vaccines can cause more local reactions (such as swelling, redness, and pain at injection site) and more systemic reactions (such as fever, body aches, and chills) as compared to non-adjuvanted vaccines.

Global Vaccine Adjuvant Market - Impact of Coronavirus (Covid-19) Pandemic:

The outbreak of COVID-19 (pandemic) has increased the use of vaccine adjuvants as there is an increase in demand for safe and effective COVID-19 vaccine across the world. Moreover, players in the market are focusing on developing novel vaccine candidates against COVID-19, as well as against infectious and chronic diseases. For instance, in October 2022, Novavax, Inc. announced that the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373), received the emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) to provide a first booster dose at least six months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older.

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/vaccine-adjuvant-market-1731

Key Takeaways:

The global vaccine adjuvant market was valued at US$ 1,430.0 Mn in 2021 and is forecast to reach a value of US$ 3,521.5 Mn by 2028 at a CAGR of 13.7% between 2022 and 2028.

Among type Mineral Salt-based Adjuvant segment held dominant position in the global vaccine adjuvant market in 2021, accounting for 37.7% share in terms of value, increasing approval and launch of new products is expected to propel growth of the segment during the forecast period.

Market Trends:

Adjuvants such as aluminum salts are used as additives in vaccines to enhance immune responses. Aluminum salts include such as aluminum phosphate, aluminum potassium sulfate, and aluminum hydroxide. Furthermore, aluminum-based salts are also used for research purposes to enhance the effectiveness of vaccines. Thus, with the increase in demand for safe and effective vaccine across the globe, the usage of such vaccine adjuvants is also increasing rapidly. This trend is expected to continue over the forecast period, driving the growth of the market.

Competitive Landscape:

Major players operating in the global vaccine adjuvant market include Thermo Fisher Scientific Inc., Air Liquide (Seppic), Pacific GeneTech Limited, OZ Biosciences, Novavax Inc., Merck & Co. Inc., InvivoGen, GlaxoSmithKline PLC, Dynavax Technologies Corporation, CSL Limited, Croda International PLC, Vertellus, Aphios Corporation, Agenus Inc., Adjuvatis, and Associated British Foods PLC (SPI Pharma Inc.), among others.

Recent Developments:

In February 2022, Seqirus invested in a new Research and Development (R&D) facility to support the company's growing R&D portfolio, with focus on self-amplifying messenger RNA (sa-mRNA) technology platform, the next generation of mRNA technology.

In November 2021, Vertellus acquired businesses of Chemtrade Logistics Income responsible for producing potassium chloride, caustic pellets, and vaccine adjuvants.

In April 2021, CSL Behring agreed with the Australian government and AstraZeneca for the local production of AstraZeneca COVID-19 vaccines.

In February 2021, Dynavax Technologies Corporation and Coalition for Epidemic Preparedness Innovations (CEPI) agreed to support the supply of Dynavax's CpG 1018 advanced adjuvant to be used in approved COVID-19 vaccines developed by CEPI grantees.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail


Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.